CD8A and cancer: While doxorubicin exerts its primary anticancer effects by intercalating between DNA base pairs, disrupting DNA structure, and inhibiting topoisomerase II in dividing cancer cells (61), it also induces immunogenic cell death and stimulates the immune system by promoting the production and activation of CD8 + T cells that specifically recognize and target tumors (62).